Friday 6 November 2026 Export EW’s income statement to Excel — free account

Edwards Lifesciences Corporation

Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024.

Revenue: +10.5%
EPS: +6.00%
Free cash flow: −1.84%
Total debt: +0.10%

Quarter to September 2026, against a year earlier

102.01 1.19 +1.18%

Follow EW

Alert me

Market cap: $58.1B
P/E: 56.7×
Fwd P/E: 36.5×
Dividend yield: —
F-score: 5/9
Altman Z: 11.54
Beneish M: −2.48
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Edwards Lifesciences Corporation 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Nov 4, 2026 · accepted 4:24 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 5, 2025: 23 added · 8 removed · 34 modified; 5 with only figures updated; 1 moved without change

Edwards Lifesciences Corporation 10-Q filed Nov 4, 2026

What changed

Stockrow Weekly